1. European Medicines Agency (2011) CHMP assessment report for Eliquis; INN apixaban. 18/05/2011 Eliquis -EMEA/H/C/002148 Doc. Ref. EMA/663351/2012. http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Summary_for_the_public/human/002148/WC500107773.pdf. Zugegriffen: 18. Nov. 2013
2. European Medicines Agency (2008) CHMP assessment report for Pradaxa, INN dabigatran etexilate. Procedure No. EMEA/H/C/000829 Doc. Ref. EMA/544606/2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf. Zugegriffen: 18. Nov. 2013
3. European Medicines Agency (2008) CHMP assessment report for Xarelto; INN rivaroxaban. Procedure No. EMEA/H/C/000944. Doc.Ref. EMA/373625/2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000944/WC500057109.pdf. Zugegriffen: 18. Nov. 2013
4. Strobeck JE (2012) Stroke prevention in atrial fibrillation: managing the risks in light of new oral anticoagulants. Cardiovasc Drugs Ther 26:331–338
5. Heidinger K, Kemkes-Matthes B (2011) Neue Antithrombotika. Wirkprinzip, Monitoring und Blutungsmanagement. Med Klein Intensivmed 106:198–204